Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions (NYSE: EBS) announced a new $50 million stock repurchase program authorized by the Board, effective through March 31, 2027, replacing a prior authorization that expired March 27, 2026.
The prior program allowed up to $50 million; the company repurchased $24.8 million under that plan. Repurchases may occur on the open market or in privately negotiated transactions and may be suspended at any time. The company had approximately 52 million shares outstanding as of February 19, 2026.
Emergent BioSolutions (NYSE: EBS) announced multiyear contracts and a contract modification with the Public Health Agency of Canada and Department of National Defence valued at up to approximately CAD 140 million. Emergent expects more than CAD 35 million in orders in 2026 and will supply four medical countermeasures, several made at its Health Canada–licensed facility to strengthen domestic production and surge capacity.
Committed annual procurements aim to ensure continuous production, rapid conversion to finished product, and long-term strategic stockpiling to support Canada's biodefence readiness.
Emergent BioSolutions (NYSE: EBS) announced FDA approval of an sNDA on Feb 12, 2026, for OTC NARCAN® Nasal Spray multipacks in new 6-count and 24-count configurations.
The multipacks are designed for higher-volume distribution, will be sold to public interest customers via NARCANDirect, and complement a January 2026 FDA approval of the NARCAN carrying case. Existing product formats will remain available. Since 2016, more than 85 million doses have been distributed in the U.S. and Canada.
Emergent BioSolutions (NYSE: EBS) will report fourth quarter and full year 2025 financial results and host a conference call on Thursday, February 26, 2026 at 5:00 PM ET.
Investors can join via live webcast on the company’s Investors page or by telephone after registering in advance; a replay will be posted on the Investors page.
Emergent BioSolutions (NYSE:EBS) announced FDA approval of a supplemental NDA to package OTC NARCAN® Nasal Spray in a new compact carrying case that holds two blister-packed doses with a Quick Start Guide. The case is designed for discretion and daily carry to improve readiness during opioid emergencies. Company survey data cited 74% overall and 81% among college students preferring a discreet carrying case. The release notes only 10% of consumers currently carry naloxone. The carrying case will be available soon at select retailers, online, and via NARCANDirect. Since 2016, the company reports > 85 million doses distributed in the U.S. and Canada.
Emergent BioSolutions (NYSE: EBS) said it made a voluntary prepayment of $100 million on its term loan in late December 2025 using cash on hand. The company reported that, since 2023 and with this prepayment, its gross debt has been reduced by $275 million to $593 million (pro forma as of September 30, 2025), a 32% decline in total debt since beginning its multi-year transformation plan. Management said the move improves financial flexibility and supports long-term stability and strategic initiatives. Emergent will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 PM PST.
Emergent BioSolutions (NYSE: EBS) received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax (Anthrax Vaccine Adsorbed) in 2026. The order is placed under Emergent’s existing IDIQ contract W911SR24D0001, led by the Capability Program Executive CBRND in collaboration with the Defense Health Agency. Deliveries will occur in 2026 and the order includes a one-year base period plus two option periods covering 2027 and 2028. The company said the award continues its partnership to provide anthrax vaccination for military personnel at elevated risk.
Emergent BioSolutions (NYSE: EBS) agreed to provide additional financial support to continue the Africa CDC-led MpOx Study in Africa (MOSA), a double-blind, platform-adaptive clinical trial launched in 2024 to evaluate treatments for mpox.
An independent data and safety monitoring board completed an initial safety review in December 2025 after 50 patients were randomized and recommended continuation with no safety concerns identified. Africa CDC and PANTHER plan to extend MOSA to additional countries, including a site in Uganda, and enroll more patients toward the next milestone.
The release notes there is currently no dedicated antiviral therapy for mpox and cites Africa CDC case totals of 61,383 confirmed cases and 296 deaths across 32 countries since 2024.
Emergent BioSolutions (NYSE: EBS) announced that Joe Papa, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 PM PST. An audio link to the session will be available and kept live for up to 30 days. The company said its presentation slides will be posted on the Investors section of the Emergent website at the time of the presentation.
Emergent BioSolutions (NYSE: EBS) announced that the U.S. FDA approved its supplemental BLA on Dec 12, 2025 to add the company's Winnipeg, Canada facility as a drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for treatment and prophylaxis of inhalational anthrax.
The Winnipeg site is described as USMCA-compliant with over 45 years of therapeutics manufacturing experience and capabilities for drug substance, fill/finish, and analytical testing. The approval follows a May 2024 operational plan to consolidate manufacturing in Winnipeg and Lansing as part of a multi-year transformation strategy.